The COVID Project
The record
- Jurisdiction
- United States (federal); Drug Enforcement Administration, Diversion Control Division
- Level
- Federal
- Authority
- 21 U.S.C. 829(a); 21 C.F.R. 1306.11(d), 290.10; 21 C.F.R. 1307.03
- Issued
- 2020-03-27 Mar. 27, 2020
- Effective
- 2020-03-27 (digitally signed Mar. 28, 2020) (read as 2020-03-27)
- End
- For the duration of the public health emergency (unless modified or withdrawn by DEA) (read as 2021-09-30)
- In force
- Mar. 27, 2020 to Sept. 30, 2021
- Quarters
- 2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
- Limitation types
- Health care ordersOther
- Addressees
- practitioner registrants
- pharmacists
- Functions reached
- CL clinical prescribing
- RT pharmacy dispensing
- CB patients
- Collection
- Other federal health agencies AGY-FED-HEALTH-OTHER
Operative words
DEA provides the following guidance on this topic and announces temporary exceptions. These exceptions shall remain in place for the duration of the Public Health Emergency (unless modified or withdrawn by DEA).... DEA acknowledges, however, that the Public Health Emergency is likely creating emergency situations, as defined by 21 CFR 290.10, with increased frequency.
Enforcement
Prescription-form requirements under 21 U.S.C. 829(a) and 842
Notes
Extended the seven-day period for delivering the written follow-up prescription to fifteen days and permitted photographed or scanned prescriptions to the pharmacy.